184 related articles for article (PubMed ID: 35250278)
21. EZH2 inhibitor Tazemetostat synergizes with JQ-1 in esophageal cancer by inhibiting c-Myc signaling pathway.
Ding N; You A; Zhao S; Yang H; Lai C; Ye F
Med Oncol; 2023 Aug; 40(10):281. PubMed ID: 37634215
[TBL] [Abstract][Full Text] [Related]
22. Positive Results for Tazemetostat in Follicular Lymphoma.
Cancer Discov; 2018 Aug; 8(8):OF3. PubMed ID: 29980507
[TBL] [Abstract][Full Text] [Related]
23. Enhancer of zeste homolog 2 (EZH2) inhibitors.
Gulati N; Béguelin W; Giulino-Roth L
Leuk Lymphoma; 2018 Jul; 59(7):1574-1585. PubMed ID: 29473431
[TBL] [Abstract][Full Text] [Related]
24. Pharmacology and pharmacokinetics of tazemetostat.
Orleni M; Beumer JH
Cancer Chemother Pharmacol; 2024 May; 93(5):509-517. PubMed ID: 38520556
[TBL] [Abstract][Full Text] [Related]
25. EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell Activation Signaling in DLBCL.
Brach D; Johnston-Blackwell D; Drew A; Lingaraj T; Motwani V; Warholic NM; Feldman I; Plescia C; Smith JJ; Copeland RA; Keilhack H; Chan-Penebre E; Knutson SK; Ribich SA; Raimondi A; Thomenius MJ
Mol Cancer Ther; 2017 Nov; 16(11):2586-2597. PubMed ID: 28835384
[TBL] [Abstract][Full Text] [Related]
26. [Epigenetic modification as a therapeutic approach for B-cell lymphoma].
Nishikori M; Takaori-Kondo A
Rinsho Ketsueki; 2022; 63(4):313-321. PubMed ID: 35491222
[TBL] [Abstract][Full Text] [Related]
27. Emerging EZH2 Inhibitors and Their Application in Lymphoma.
Lue JK; Amengual JE
Curr Hematol Malig Rep; 2018 Oct; 13(5):369-382. PubMed ID: 30112706
[TBL] [Abstract][Full Text] [Related]
28. Parallel testing of liquid biopsy (ctDNA) and tissue biopsy samples reveals a higher frequency of EZH2 mutations in follicular lymphoma.
Nagy Á; Bátai B; Kiss L; Gróf S; Király PA; Jóna Á; Demeter J; Sánta H; Bátai Á; Pettendi P; Szendrei T; Plander M; Körösmezey G; Alizadeh H; Kajtár B; Méhes G; Krenács L; Timár B; Csomor J; Tóth E; Schneider T; Mikala G; Matolcsy A; Alpár D; Masszi A; Bödör C
J Intern Med; 2023 Sep; 294(3):295-313. PubMed ID: 37259686
[TBL] [Abstract][Full Text] [Related]
29. Tazemetostat for the treatment of multiple types of hematological malignancies and solid tumors.
Marsh S; Jimeno A
Drugs Today (Barc); 2020 Jun; 56(6):377-387. PubMed ID: 32525136
[TBL] [Abstract][Full Text] [Related]
30. Novel Therapy Approaches to Follicular Lymphoma.
Northend M; Townsend W
Drugs; 2021 Mar; 81(4):453-469. PubMed ID: 33616890
[TBL] [Abstract][Full Text] [Related]
31. Initial testing (stage 1) of tazemetostat (EPZ-6438), a novel EZH2 inhibitor, by the Pediatric Preclinical Testing Program.
Kurmasheva RT; Sammons M; Favours E; Wu J; Kurmashev D; Cosmopoulos K; Keilhack H; Klaus CR; Houghton PJ; Smith MA
Pediatr Blood Cancer; 2017 Mar; 64(3):. PubMed ID: 27555605
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of Tazemetostat as a Therapeutically Relevant Substance in Biliary Tract Cancer.
Bekric D; Neureiter D; Ablinger C; Dobias H; Beyreis M; Ritter M; Jakab M; Bischof J; Koller U; Kiesslich T; Mayr C
Cancers (Basel); 2023 Mar; 15(5):. PubMed ID: 36900361
[TBL] [Abstract][Full Text] [Related]
33. A LYSA Phase Ib Study of Tazemetostat (EPZ-6438) plus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) with Poor Prognosis Features.
Sarkozy C; Morschhauser F; Dubois S; Molina T; Michot JM; Cullières-Dartigues P; Suttle B; Karlin L; Le Gouill S; Picquenot JM; Dubois R; Tilly H; Herbaux C; Jardin F; Salles G; Ribrag V
Clin Cancer Res; 2020 Jul; 26(13):3145-3153. PubMed ID: 32122924
[TBL] [Abstract][Full Text] [Related]
34. Chemotherapy-Free Management of Follicular and Marginal Zone Lymphoma.
Ollila TA; Olszewski AJ
Cancer Manag Res; 2021; 13():3935-3952. PubMed ID: 34017197
[TBL] [Abstract][Full Text] [Related]
35. EZH2 alterations in follicular lymphoma: biological and clinical correlations.
Huet S; Xerri L; Tesson B; Mareschal S; Taix S; Mescam-Mancini L; Sohier E; Carrère M; Lazarovici J; Casasnovas O; Tonon L; Boyault S; Hayette S; Haioun C; Fabiani B; Viari A; Jardin F; Salles G
Blood Cancer J; 2017 Apr; 7(4):e555. PubMed ID: 28430172
[TBL] [Abstract][Full Text] [Related]
36. Overcoming clinical resistance to EZH2 inhibition using rational epigenetic combination therapy.
Kazansky Y; Cameron D; Mueller HS; Demarest P; Zaffaroni N; Arrighetti N; Zuco V; Kuwahara Y; Somwar R; Ladanyi M; Qu R; De Stanchina E; Dela Cruz FS; Kung AL; Gounder M; Kentsis A
bioRxiv; 2023 Dec; ():. PubMed ID: 36798379
[TBL] [Abstract][Full Text] [Related]
37. Epigenetics of Indolent Lymphoma and How It Drives Novel Therapeutic Approaches-Focus on EZH2-Targeted Drugs.
Longley J; Johnson PWM
Curr Oncol Rep; 2021 May; 23(7):76. PubMed ID: 33937922
[TBL] [Abstract][Full Text] [Related]
38. Chromatin modifying gene mutations in follicular lymphoma.
Green MR
Blood; 2018 Feb; 131(6):595-604. PubMed ID: 29158360
[TBL] [Abstract][Full Text] [Related]
39. ADCs, BiTEs, CARs, and Small Molecules: A New Era of Targeted Therapy in Non-Hodgkin Lymphoma.
Abramson JS; Ghosh N; Smith SM
Am Soc Clin Oncol Educ Book; 2020 May; 40():302-313. PubMed ID: 32421455
[TBL] [Abstract][Full Text] [Related]
40. Copanlisib in the Treatment of Relapsed Follicular Lymphoma: Utility and Experience from the Clinic.
Chauhan AF; Cheson BD
Cancer Manag Res; 2021; 13():677-692. PubMed ID: 33531838
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]